Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GDC-0810 versus fulvestrant in postmenopausal women with advanced or metastatic ER-positive/HER2-negative breast cancer resistant to aromatase inhibitor therapy
2015-000106-19Phase 2Completed
- Sponsor
- Roche
- Start
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of brilanestrant in breast cancer (2 arms), sponsored by Roche. Primary endpoint: Progression-free survival. Started Aug 2015; status: completed.
02
Drugs
brilanestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2015-000106-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000106-19.